Latest news

Thumbnail image for US clears first enzyme therapy for PKU

US clears first enzyme therapy for PKU

Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.

25th May 2018

Thumbnail image for Imbruvica/Gazyva combo improves PFS in CLL patients

Imbruvica/Gazyva combo improves PFS in CLL patients

A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage clinical trial.

25th May 2018

Thumbnail image for NICE issues decision on Mylotarg, Besponsa for leukaemia

NICE issues decision on Mylotarg, Besponsa for leukaemia

The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).

25th May 2018

Thumbnail image for NICE rejects Chiesi’s Lamzede

NICE rejects Chiesi’s Lamzede

It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.

24th May 2018

Thumbnail image for Tax rises needed to boost health and social care funding

Tax rises needed to boost health and social care funding

Tax rises will likely be needed to keep the quality of health and social care as it is now while the system contends with the growing demands of an ageing demographic, concludes a report by The Institute for Fiscal Studies and the Health Foundation.

24th May 2018

Thumbnail image for EU approves Repatha for reduction of CV risk

EU approves Repatha for reduction of CV risk

The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).

23rd May 2018

Previous  --   8 9 10 11 12 13 14 15 16 17   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download